| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2006-10-17 09:58:23 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005032 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Cetirizine |
|---|
| Description | Cetirizine is a medication used for the treatment of allergies, hay fever, angioedema, and hives. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors. It is a major metabolite of hydroxyzine, and has the same basic side effects, including dry mouth. A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. Cetirizine hydrochloride is a medication used for the treatment of allergies, hay fever, angioedema, and hives. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors. It is a major metabolite of hydroxyzine, and has the same basic side effects, including dry mouth. |
|---|
| Structure | OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1 InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26) |
|---|
| Synonyms | | Value | Source |
|---|
| Cetirizin | ChEBI | | Cetirizina | ChEBI | | Cetirizinum | ChEBI | | Cetiderm | Kegg | | Benaday | HMDB | | Cetirizine hydrochloride | HMDB | | Humex | HMDB | | Reactine | HMDB, MeSH | | Virlix | HMDB, MeSH | | Zirtek | HMDB, MeSH | | Zyrlex | HMDB | | Zyrtec | HMDB, MeSH | | Alpharma brand OF cetirizine dihydrochloride | MeSH, HMDB | | Ceti-puren | MeSH, HMDB | | CetiLich | MeSH, HMDB | | Cetirigamma | MeSH, HMDB | | Cetirizin al | MeSH, HMDB | | Dihydrochloride, cetirizine | MeSH, HMDB | | glaxo Wellcome brand OF cetirizine dihydrochloride | MeSH, HMDB | | TAD brand OF cetirizine dihydrochloride | MeSH, HMDB | | UCB brand OF cetirizine dihydrochloride | MeSH, HMDB | | Voltric | MeSH, HMDB | | CT-Arzneimittel brand OF cetirizine dihydrochloride | MeSH, HMDB | | Azupharma brand OF cetirizine dihydrochloride | MeSH, HMDB | | Basics brand OF cetirizine dihydrochloride | MeSH, HMDB | | Cetalerg | MeSH, HMDB | | Dermapharm brand OF cetirizine dihydrochloride | MeSH, HMDB | | Krewel brand OF cetirizine dihydrochloride | MeSH, HMDB | | Lacer brand OF cetirizine dihydrochloride | MeSH, HMDB | | Menarini brand OF cetirizine dihydrochloride | MeSH, HMDB | | Pfizer brand OF cetirizine dihydrochloride | MeSH, HMDB | | Pfizer consumer healthcare brand OF cetirizine dihydrochloride | MeSH, HMDB | | UCB pharma brand OF cetirizine dihydrochloride | MeSH, HMDB | | AWD.pharma brand OF cetirizine dihydrochloride | MeSH, HMDB | | Aliud brand OF cetirizine dihydrochloride | MeSH, HMDB | | Ceti tad | MeSH, HMDB | | Cetidura | MeSH, HMDB | | Cetirizin azu | MeSH, HMDB | | Cetirizine dihydrochloride | MeSH, HMDB | | Cetirlan | MeSH, HMDB | | Lichtenstein brand OF cetirizine dihydrochloride | MeSH, HMDB | | Rodleben brand OF cetirizine | MeSH, HMDB | | United drug brand OF cetirizine dihydrochloride | MeSH, HMDB | | Wolff brand OF cetirizine dihydrochloride | MeSH, HMDB | | (2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid | MeSH, HMDB | | Alerlisin | MeSH, HMDB | | Ceterifug | MeSH, HMDB | | Cetil von CT | MeSH, HMDB | | Cetirizin basics | MeSH, HMDB | | Merck dura brand OF cetirizine dihydrochloride | MeSH, HMDB | | Sanofi synthelabo brand OF cetirizine dihydrochloride | MeSH, HMDB | | Wörwag brand OF cetirizine dihydrochloride | MeSH, HMDB | | Zetir | MeSH, HMDB |
|
|---|
| Chemical Formula | C21H25ClN2O3 |
|---|
| Average Molecular Weight | 388.888 |
|---|
| Monoisotopic Molecular Weight | 388.155370383 |
|---|
| IUPAC Name | 2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
|---|
| Traditional Name | cetirizine |
|---|
| CAS Registry Number | 83881-51-0 |
|---|
| SMILES | OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1 |
|---|
| InChI Identifier | InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26) |
|---|
| InChI Key | ZKLPARSLTMPFCP-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as diphenylmethanes. Diphenylmethanes are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Diphenylmethanes |
|---|
| Direct Parent | Diphenylmethanes |
|---|
| Alternative Parents | |
|---|
| Substituents | - Diphenylmethane
- Chlorobenzene
- Halobenzene
- N-alkylpiperazine
- Aralkylamine
- Aryl halide
- 1,4-diazinane
- Aryl chloride
- Piperazine
- Amino acid
- Amino acid or derivatives
- Tertiary amine
- Tertiary aliphatic amine
- Organoheterocyclic compound
- Carboxylic acid derivative
- Carboxylic acid
- Dialkyl ether
- Monocarboxylic acid or derivatives
- Azacycle
- Ether
- Organic oxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Organohalogen compound
- Amine
- Organochloride
- Organonitrogen compound
- Carbonyl group
- Hydrocarbon derivative
- Organooxygen compound
- Organic oxide
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 112.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter)). Predicted by Afia on May 17, 2022. | 3.85 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.6854 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.74 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 71.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized |
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Cetirizine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0udr-3292000000-e20abaab20740ce81a18 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Cetirizine GC-MS (1 TMS) - 70eV, Positive | splash10-0uds-7498000000-d6daecf118171395d6b7 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Cetirizine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Cetirizine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Cetirizine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000j-0900000000-9801bb859e79fa9922aa | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-014b559d56b0f32984ff | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-213bd47e17d5ab69ad4b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-004r-9006000000-f496e22c8e0e293fe98c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-d8a55ab1a7aff0580a91 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-d8a55ab1a7aff0580a91 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-dc957bb6f947575ae4fa | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000b-0900000000-48fc0581ff9fff15e16d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-04ca95fadd952d0aaeb8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-000i-0009000000-014b559d56b0f32984ff | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-0006-0009000000-26a7769df28c2325ec53 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , negative-QTOF | splash10-0006-0009000000-284c2e7b25733d7c9875 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-QFT , negative-QTOF | splash10-000i-0009000000-04befed283d691217ba2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-0udi-0190000000-14715ff4d57580fbb166 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-0f79-0069000000-431df9c3533b77cf08bc | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-0udi-0090000000-e042b67e2048318e7dbd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-0udi-0190000000-b0dfb67717c01fd0c0b9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-0gb9-0970000000-e2810b242fefb4a419e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Cetirizine LC-ESI-ITFT , positive-QTOF | splash10-014i-0900000000-72f7cddc4ff6d45f98c0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 10V, Positive-QTOF | splash10-000i-0019000000-e2cc239f762011eb0c4d | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 20V, Positive-QTOF | splash10-0w2i-1169000000-185e6899ae017256a767 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 40V, Positive-QTOF | splash10-0udi-3391000000-bfd70499959ae71093eb | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 10V, Negative-QTOF | splash10-000i-0009000000-caf1604c9603d45a6712 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 20V, Negative-QTOF | splash10-000i-1119000000-61c40cd9a0e9b76b5e91 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Cetirizine 40V, Negative-QTOF | splash10-056r-9162000000-08731719ee47b215e4c7 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | Not Available |
|---|
| Biospecimen Locations | |
|---|
| Tissue Locations | |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| Not Available |
|---|
| Predicted Concentrations |
|---|
| |
| Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | None |
|---|
| Associated OMIM IDs | None |
|---|
| External Links |
|---|
| DrugBank ID | Not Available |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 2577 |
|---|
| KEGG Compound ID | C07778 |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Cetirizine |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | Not Available |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 3561 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | Not Available |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Cossement, Eric; Motte, Genevieve; Bodson, Guy; Gobert, Jean. A., Process for preparation of cetirizine, its dihydrochloride, and optical isomers via hydrolysis and corresponding nitriles. Brit. UK Pat. Appl. (1990), 13 pp. |
|---|
| Material Safety Data Sheet (MSDS) | Download (PDF) |
|---|
| General References | - Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093 ]
- Purohit A, Melac M, Pauli G, Frossard N: Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol. 2004 Jun;92(6):635-40. [PubMed:15237765 ]
- Ramboer I, Bumtbacea R, Lazarescu D, Radu JR: Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J Int Med Res. 2000 Mar-Apr;28(2):69-77. [PubMed:10898119 ]
- Purohit A, Duvernelle C, Melac M, Pauli G, Frossard N: Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol. 2001 Apr;86(4):387-92. [PubMed:11345280 ]
- Townley RG, Okada C: Use of cetirizine to investigate non-H1 effects of second-generation antihistamines. Ann Allergy. 1992 Feb;68(2):190-6. [PubMed:1346737 ]
- Brik A, Tashkin DP, Gong H Jr, Dauphinee B, Lee E: Effect of cetirizine, a new histamine H1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma. J Allergy Clin Immunol. 1987 Jul;80(1):51-6. [PubMed:2885355 ]
- Fadel R, Herpin-Richard N, Rihoux JP, Henocq E: Inhibitory effect of cetirizine 2HCl on eosinophil migration in vivo. Clin Allergy. 1987 Jul;17(4):373-9. [PubMed:2887304 ]
- Petersen LJ, Church MK, Rihoux JP, Skov PS: Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy. 1999 Jun;54(6):607-11. [PubMed:10435475 ]
- Siergiejko Z, Michalska I, Rogalewska A, Chyrek-Borowska S: [Effect of cetirizine, selective H1 antagonist of histamine on skin and bronchial reactivity and cellular histamine release in allergic diseases]. Pneumonol Alergol Pol. 1992;60(11-12):22-7. [PubMed:1303774 ]
- Atkins PC, Zweiman B, Moskovitz A, von Allmen C, Ciliberti M: Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine. J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):806-11. [PubMed:9215249 ]
- Simons FE, Murray HE, Simons KJ: Quantitation of H1-receptor antagonists in skin and serum. J Allergy Clin Immunol. 1995 Mar;95(3):759-64. [PubMed:7897161 ]
|
|---|